-The Hindu Business Line Through the ‘Sukrutham' scheme, the Kerala Government aims to take advanced cancer treatment to the poorest Kerala: "We have two options, medically and emotionally: give up or fight like hell," Lance Armstrong, champion cycle racer, who recovered from advanced testicular cancer once said about his battle against cancer. The American, fortunately, had the money to pay for the extremely expensive treatment. But, for the majority of 1.75 lakh...

-Kafila.org Dear Prime Minister Modi ji, We, the undersigned, wish to share with you some of our concerns on India's position on intellectual property (IP), particularly in the context of bilateral relations between the United States of America and India. We gather from the US-India Joint Statement dated 30 September 2014 that the Indian Government (a)greeing on the need to foster innovation in a manner that promotes economic growth...

-Asia News Network A controversy is brewing over a new cure for hepatitis C because it is extremely expensive and patients in middle-income countries like Malaysia will find it way beyond their budget. There are an estimated 400,000 Malaysians with hepatitis C, but this is probably a significant under-estimate since many people are not aware that they have the virus. Worldwide, 170 million people live with the hepatitis C virus (HCV), and every...

-The Indian Express Prime Minister Narendra Modi's US visit is likely to throw up highly contentious intellectual property rights issues. Indeed, for the last several years, US drug majors and their European counterparts have lobbied hard to demonise the Indian patent regime. But the government must continue to defend the law and stand its ground. Particularly since our own industrial moguls have caved in and are less vocal about their opposition...

-The Business Standard A ray of hope for Indian generic drug makers Gilead Sciences, the California-headquartered biotechnology company, has authorised seven India-based drug makers - Cipla, Ranbaxy, Mylan, Strides Arcolab, Hetero, Cadila Healthcare and Sequent Scientific - to manufacture and sell the generic versions of its hepatitis C medicine, Sovaldi, in 91 developing countries. Earlier in the week, Lupin, the fourth largest Indian drug maker, announced that it will develop and supply...